ANDREW M. CUOMO
Governor

HOWARD A. ZUCKER, M.D., J.D.
Acting Commissioner

SALLY DRESLIN, M.S., R.N.
Executive Deputy Commissioner

Medicaid Fee- for- Service Providers
Dispense Brand Name Drug when Less Expensive than Generic Program

Effective immediately Wellbutrin 75mg will be removed from the program due to market availability issues.

Effective 04/19/2016, the following changes will be made to the Dispense Brand Name Drug when Less Expensive than Generic Program:

- **Cymbalta, Kapvay, Renvela tablet, Voltaren Gel** and **Nasonex** will be **added** to the program.
- **Wellbutrin 100mg** will be **removed** from the program.

In conformance with State Education Law which intends that patients receive the lower cost alternative, brand name drugs included in this program:

- **Do not require 'Dispense as Written' (DAW) or 'Brand Medically Necessary' on the prescription.**
- Have a generic copayment.
- Are paid at the Brand Name Drug reimbursement rate or usual and customary price,   whichever is lower (SMAC/FUL are not applied).
- Do not require a new prescription if the drug is removed from this program.

IMPORTANT BILLING INFORMATION
Prescription claims submitted to the Medicaid program **do not require** the submission of Dispense as Written/Product Selection Code of '1'; **Pharmacies can submit any valid NCPDP field (408-D8) value.**

List of Brand Name Drugs included in this program* *(Updated): 04/07/2016*

Abilify	Epivir HBV tablet	Pulmicort Respules
Adderall XR	Exelon Patch	**Renvela tablet**
Aggrenox	Focalin XR 5mg, 10mg, 15mg,20mg,30mg,40mg	Soriatane
Aldara	Gabitril 2mg, 4mg	Tegretol suspension
Alphagan P 0.15%	Gleevec	Tegretol XR
Astepro	Hepsera	Tobradex suspension
Baraclude	**Kapvay**	Tricor
Catapres-TTS	Mepron	Trilipix
Cellcept suspension	Myfortic	Trizivir
Combivir	**Nasonex**	Valcyte
Copaxone 20ml SQ	Niaspan	**Voltaren Gel**
Cymbalta	Patanase	Xeloda
Diastat	Protopic	Xenazine

*List is subject to change

 Please keep in mind that drugs in this program may be subject to prior authorization requirements of other pharmacy programs, promoting the use of the most cost-effective product.